Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence

NCT04741737 · tracked via the Priya Life Science South Korea tracker

Sponsor

Gangnam Severance Hospital

Phase

Not applicable

Started

2020-03-01

Last updated

2023-10-11

Condition(s) studied

Mastectomy

Investigational drug(s) / intervention(s)

reSLNB arm

reSLNB arm: Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.

Study summary

According to the standard treatment guidelines established until recently, in the case of ipsilateral breast tumor recurrence without systemic metastasis, salvage mastectomy or lumpectomy can be performed when either partial or whole breast radiation therapy is possible. On the other hand, there are currently no standard treatment guidelines for axillary treatment, and the evidence for this is limited. Axillary lymph node metastasis was reported to occur in about 26% of breast cancer patients who had negative sentinel lymph nodes from previous surgery for primary breast cancer and only local recurrence occurred. It is still important in the decision of treatment or adjuvant radiation therapy. However, it is known that most of the patients with ipsilateral breast recurrence do not have axillary lymph node metastasis. Therefore, performing axillary axillary surgery in all of these patients does not help the patient's survival in many cases, but rather can lead to complications such as lymphedema and seroma and postoperative wound infection. A question about the implementation of axillary lymph node resection has been raised and for this reason, it is necessary to study whether surveillance lymph node biopsy is still effective in patients with recurrence in the ipsilateral breast.

Most of the studies on ipsilateral breast tumor recurrence without systemic metastasis reported to date are case reports or small retrospective studies. In addition, the combined meta-analysis also has limitations in that the study design is not uniform, and there are many cases in which primary breast cancer surgery performed total mastectomy or axillary lymph node dissection. This study is a multicenter prospective study designed to validate the clinical effectiveness of repeat-SLNB conducted in patients with ipsilateral breast tumor recurrence among patients who previously underwent breast conservation and sentinel lymph node biopsy for unilateral primary breast cancer.

Eligibility

Sex

FEMALE

Min age

19 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age over 19 years old 2. Patients who are expected to undergo surgery under the diagnosis of ipsilateral breast tumor recurrence(histologically confirmed in situ disease or invasive disease) 3. Patients who had partial mastectomy and sentinel lymph node biopsy for prior operation for the initially diagnosed breast cancer 4. Patients considered to be axillary lymph node negative from clinical findings 5. Patients who understand and willingly participate in the study Exclusion Criteria: 1. Patients with recurrence in other regions. (e.g. ipsilateral axillary lymph node, supraclavicular lymph node, internal mammary lymph node, etc.) 2. Patients who are not eligible to perform SLNB 3. Patients who received mastectomy or axillary lymph node dissection for prior operation 4. Patients who experienced recurrence within a year from the primary operation 5. Patientes who are known to have axillary lymph node metastasis before the secondary operation, histologically confirmed from tissue biopsy or cytology 6. Patients with systemic recurrence 7. Patients with inflammatory breast cancer 5\) Pregnant and lactating patients

Primary outcome measure(s)

5 year disease free survival — 5 years after surgery (re-SLNB)
To prove non-inferiority of re-SLNB compared to ALND regarding disease free survival

Trial sites (1)

Facility	City	Region	Status
Gangnam Severance Hospital, Yonsei University College of Medicine	Seoul	South Korea	Recruiting

More Gangnam Severance Hospital trials in South Korea

Quantitative Analysis of EEG Changes in Response to Nociception Recruiting

Comparison of Full Robotic Instrumentation and Assistant-Controlled Laparoscopic Instrumentation in Robotic Distal Gastrectomy Recruiting

Pilot Study for High Output Drainage Removal After Gastrectomy Recruiting

Wearable Ambulatory Vs. Office BP in Hemodialysis Starting soon

EEG and ANI Guided Anesthesia and Quality of Recovery Recruiting

Other trials for the same condition

A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia Recruiting

Primary Surgical Prevention of Breast Cancer-related Lymphedema Recruiting

Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04741737 on ClinicalTrials.gov ↗ ← All trials in South Korea